What are the side effects of PE-22-28?
The most commonly reported PE-22-28 side effects are limited human safety data, theoretical effects on cardiac TREK-1 channels. Most are mild and tend to be dose dependent. It is generally avoided with active SSRI / SNRI / MAOI regimens. Human clinical evidence for PE-22-28 is limited, so this reflects reported and observed effects, not a complete safety profile.
Reported PE-22-28 side effects
- Limited human safety data
- Theoretical effects on cardiac TREK-1 channels
Who should avoid it
- Active SSRI / SNRI / MAOI regimens
- Cardiac arrhythmia history
- Pregnancy / nursing
References
- PE-22-28: a novel peptide for fast-acting antidepressant treatment — Mazella J et al., PLoS Biol, 2010
- Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity — Djillani A et al., Frontiers in Pharmacology, 2017
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on PE-22-28
Last updated 2026-06-06.